Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
CCCC
#2959
C4 Therapeutics, Inc.
2.7
0
-1.46%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-1.46%
Monatliche Änderung
+26.17%
6 month change
+5.06%
Jahresänderung
+4.25%
Vorheriger Schlusskurs
2.7
4
Open
2.7
0
Bid
Ask
Low
2.7
0
High
2.7
0
Volumen
57
Märkte
Aktien
Gesundheitswesen
CCCC
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
43.12 M
48.74 M
49.05 M
68.6 M
70.99 M
97.58 M
—
Valuation ratios
Enterprise value
1.25 B
1.49 B
283.19 M
320.69 M
200.06 M
111.77 M
354.05 M
Price to earnings ratio
—
—
-2.44
-2.44
-2.37
-1.5
-4.81
Price to sales ratio
—
—
10.03
15.59
7.02
—
—
Price to cash flow ratio
—
—
2.94
3.03
3.83
1.6
5.82
Price to book ratio
—
—
1.08
1.32
1.16
0.62
1.07
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.17
0.17
0.3
0.35
0.3
0.29
0.35
Return on equity %
0.24
0.22
0.44
0.54
0.49
0.41
0.57
Return on invested capital %
460.27
313.53
258.91
346.35
357.39
364.29
418.25
Gross margin %
—
—
100
100
100
100
400
Operating margin %
—
—
416.56
669.84
336.15
320.53
1 360.45
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
412.19
638.34
295.96
292.08
1 238.66
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.69
6.36
6.46
6.34
5.71
7.81
24.32
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
0.07
0.05
0.1
0.1
0.12
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.03
0.02
0.02
0
—
—
—
Long term debt to total equity ratio
0.04
0.03
0.03
0
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.17
2.15
0.94
1.19
1.34
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
6.9
5.67
3.85
3.58
12.79
Net current asset value per share
—
—
5.89
5.46
3.72
3.11
12.41
Tangible book value per share
—
—
5.92
4.96
3.11
3.1
10.43
Working capital per share
—
—
4.97
4.6
3.06
2.72
10.32
Book value per share
—
—
5.92
4.96
3.11
3.1
10.43
Nachrichten
Barclays hebt Kursziel für C4 Therapeutics nach Studienfortschritten an
Barclays raises C4 Therapeutics stock price target on trial progress
TD Cowen bestätigt "Buy"-Rating für C4 Therapeutics nach starkem Kursanstieg
TD Cowen reiterates Buy rating on C4 Therapeutics stock
C4: EPS übertrifft Schätzungen um 0,11 $ - Umsatz besser als erwartet
C4 earnings beat by $0.11, revenue topped estimates
C4 Therapeutics: Brookline Capital Markets hebt Kursziel nach Studienfortschritten deutlich an
Brookline Capital raises C4 Therapeutics stock price target on trial progress
C4 Therapeutics: Erster Patient in Phase-2-Studie zu Multiplem Myelom behandelt
C4 Therapeutics doses first patient in phase 2 myeloma trial
C4 Therapeutics: Medizinischer Vorstand Reyno verkauft Aktien im Wert von 22.200 US-Dollar
C4 Therapeutics’ chief medical officer Reyno sells $22,200 in stock